Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer
NCT00005608 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2012-06-06
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of fluorouracil-uracil and leucovorin in treating women who have metastatic breast cancer.
Conditions
Interventions
- DRUG
-
leucovorin calcium
- DRUG
-
tegafur-uracil
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
William J. Gradishar, MD · Robert H. Lurie Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-02-29
- Primary Completion
- 2002-06-30
- Completion
- 2002-06-30
Countries
- United States
Study Locations
More Related Trials
-
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
NCT00305825 ·Status: COMPLETED ·Phase: PHASE2
-
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
NCT01205685 ·Status: TERMINATED ·Phase: PHASE2
-
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
NCT00003440 ·Status: COMPLETED ·Phase: PHASE3
-
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT03633331 ·Status: COMPLETED ·Phase: PHASE2
-
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT05524584 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
NCT00003253 ·Status: UNKNOWN ·Phase: PHASE2
-
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT05305924 ·Status: RECRUITING ·Phase: PHASE2
-
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
NCT00855114 ·Status: WITHDRAWN ·Phase: PHASE2
-
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
NCT00963729 ·Status: COMPLETED ·Phase: PHASE3
-
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
NCT00722072 ·Status: TERMINATED ·Phase: PHASE2
-
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00006104 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
NCT00023998 ·Status: COMPLETED ·Phase: PHASE2
-
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
NCT03128619 ·Status: TERMINATED ·Phase: PHASE1
-
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
NCT00134680 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
NCT02560311 ·Status: UNKNOWN
-
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
NCT02955394 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
NCT02219789 ·Status: COMPLETED ·Phase: PHASE1
-
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
NCT00503841 ·Status: TERMINATED ·Phase: NA
-
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
NCT00005635 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
NCT00015886 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
NCT01855828 ·Status: COMPLETED ·Phase: PHASE2
-
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
NCT03894007 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
NCT00567190 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03125928 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
NCT01430585 ·Status: TERMINATED ·Phase: PHASE2